Effect of early intensive multifactorial therapy on 5-year cardiovascular outcomes in individuals with type 2 diabetes detected by screening (ADDITION-Europe): a cluster-randomised trial

Simon J Griffin, Knut Borch-Johnsen, Melanie J Davies, Kamlesh Khunti, Guy E H M Rutten, Annelli Sandbæk, Stephen J Sharp, Rebecca K Simmons, Maureen van den Donk, Nicholas J Wareham, Torsten Lauritzen, Simon J Griffin, Knut Borch-Johnsen, Melanie J Davies, Kamlesh Khunti, Guy E H M Rutten, Annelli Sandbæk, Stephen J Sharp, Rebecca K Simmons, Maureen van den Donk, Nicholas J Wareham, Torsten Lauritzen

Abstract

Background: Intensive treatment of multiple cardiovascular risk factors can halve mortality among people with established type 2 diabetes. We investigated the effect of early multifactorial treatment after diagnosis by screening.

Methods: In a pragmatic, cluster-randomised, parallel-group trial done in Denmark, the Netherlands, and the UK, 343 general practices were randomly assigned screening of registered patients aged 40-69 years without known diabetes followed by routine care of diabetes or screening followed by intensive treatment of multiple risk factors. The primary endpoint was first cardiovascular event, including cardiovascular mortality and morbidity, revascularisation, and non-traumatic amputation within 5 years. Patients and staff assessing outcomes were unaware of the practice's study group assignment. Analysis was done by intention to treat. This study is registered with ClinicalTrials.gov, number NCT00237549.

Findings: Primary endpoint data were available for 3055 (99·9%) of 3057 screen-detected patients. The mean age was 60·3 (SD 6·9) years and the mean duration of follow-up was 5·3 (SD 1·6) years. Improvements in cardiovascular risk factors (HbA(1c) and cholesterol concentrations and blood pressure) were slightly but significantly better in the intensive treatment group. The incidence of first cardiovascular event was 7·2% (13·5 per 1000 person-years) in the intensive treatment group and 8·5% (15·9 per 1000 person-years) in the routine care group (hazard ratio 0·83, 95% CI 0·65-1·05), and of all-cause mortality 6·2% (11·6 per 1000 person-years) and 6·7% (12·5 per 1000 person-years; 0·91, 0·69-1·21), respectively.

Interpretation: An intervention to promote early intensive management of patients with type 2 diabetes was associated with a small, non-significant reduction in the incidence of cardiovascular events and death.

Funding: National Health Service Denmark, Danish Council for Strategic Research, Danish Research Foundation for General Practice, Danish Centre for Evaluation and Health Technology Assessment, Danish National Board of Health, Danish Medical Research Council, Aarhus University Research Foundation, Wellcome Trust, UK Medical Research Council, UK NIHR Health Technology Assessment Programme, UK National Health Service R&D, UK National Institute for Health Research, Julius Center for Health Sciences and Primary Care, University Medical Center, Utrecht, Novo Nordisk, Astra, Pfizer, GlaxoSmithKline, Servier, HemoCue, Merck.

Copyright © 2011 Elsevier Ltd. All rights reserved.

Figures

Figure 1
Figure 1
Trial profile
Figure 2
Figure 2
Cumulative incidence and relative risk of composite cardiovascular endpoint (A) Cumulative incidence curves by treatment group. The p value was calculated with Cox's regression and fixed-effects meta-analysis. (B) HRs of development of cardiovascular death, non-fatal myocardial infarction, non-fatal stroke, and revascularisation as a first event (secondary endpoints), and these cardiovascular events combined (primary endpoint), by country and overall. HR=hazard ratio. CVD=cardiovascular disease.
Figure 3
Figure 3
Cumulative incidence and relative risk of all-cause mortality (A) Kaplan-Meier survival estimates by treatment group. (B) HRs of all-cause mortality, by country and overall. HR=hazard ratio. CVD=cardiovascular disease.
Figure 4
Figure 4
Proportion of patients for whom cardiovascular risk factor values were below the intensive treatment intervention target thresholds at baseline and after 5 years of follow-up 1 SE are shown. CVD=cardiovascular disease. HbA1c=glycated haemoglobin A1c.

References

    1. IDF . IDF Diabetes Atlas. 4th edn. International Diabetes Federation; Brussels, Belgium: 2009.
    1. Gaede P, Vedel P, Larsen N, Jensen GV, Parving HH, Pedersen O. Multifactorial intervention and cardiovascular disease in patients with type 2 diabetes. N Engl J Med. 2003;348:383–393.
    1. Gaede P, Lund-Andersen H, Parving HH, Pedersen O. Effect of a multifactorial intervention on mortality in type 2 diabetes. N Engl J Med. 2008;358:580–591.
    1. UK Prospective Diabetes Study Group Tight blood pressure control and risk of macrovascular and microvascular complications in type 2 diabetes: UKPDS 38. BMJ. 1998;317:703–713.
    1. Heart Outcomes Prevention Evaluation Study Investigators Effects of ramipril on cardiovascular and microvascular outcomes in people with diabetes mellitus: results of the HOPE study and MICRO-HOPE substudy. Lancet. 2000;355:253–259.
    1. Pyorala K, Pedersen TR, Kjekshus J, Faergeman O, Olsson AG, Thorgeirsson G. Cholesterol lowering with simvastatin improves prognosis of diabetic patients with coronary heart disease. A subgroup analysis of the Scandinavian Simvastatin Survival Study (4S) Diabetes Care. 1997;20:614–620.
    1. Ray KK, Seshasai SR, Wijesuriya S. Effect of intensive control of glucose on cardiovascular outcomes and death in patients with diabetes mellitus: a meta-analysis of randomised controlled trials. Lancet. 2009;373:1765–1772.
    1. Holman RR, Paul SK, Bethel MA, Matthews DR, Neil HA. 10-year follow-up of intensive glucose control in type 2 diabetes. N Engl J Med. 2008;359:1577–1589.
    1. Harris MI, Klein R, Wellborn TA, Knuiman MW. Onset of NIDDM occurs at least 4–7yr before clinical diagnosis. Diabetes Care. 1992;15:815–819.
    1. Glumer C, Jorgensen T, Borch-Johnsen K. Prevalences of diabetes and impaired glucose regulation in a Danish population: the Inter99 study. Diabetes Care. 2003;26:2335–2340.
    1. Eborall HC, Griffin SJ, Prevost AT, Kinmonth AL, French DP, Sutton S. Psychological impact of screening for type 2 diabetes: controlled trial and comparative study embedded in the ADDITION (Cambridge) randomised controlled trial. BMJ. 2007;335:486.
    1. Wareham NJ, Griffin SJ. Should we screen for type 2 diabetes? Evaluation against national screening committee criteria. BMJ. 2001;322:986–988.
    1. Kahn R, Alperin P, Eddy D. Age at initiation and frequency of screening to detect type 2 diabetes: a cost-effectiveness analysis. Lancet. 2010;375:1365–1374.
    1. Glumer C, Yuyun M, Griffin S. What determines the cost-effectiveness of diabetes screening? Diabetologia. 2006;49:1536–1544.
    1. Lauritzen T, Griffin S, Borch-Johnsen K, Wareham NJ, Wolffenbuttel BH, Rutten G. The ADDITION study: proposed trial of the cost-effectiveness of an intensive multifactorial intervention on morbidity and mortality among people with Type 2 diabetes detected by screening. Int J Obes Relat Metab Disord. 2000;24(suppl 3):S6–S11.
    1. Echouffo-Tcheugui JB, Simmons RK, Williams KM. The ADDITION-Cambridge trial protocol: a cluster-randomised controlled trial of screening for type 2 diabetes and intensive treatment for screen-detected patients. BMC Public Health. 2009;9:136.
    1. Webb DR, Khunti K, Srinivasan B. Rationale and design of the ADDITION-Leicester study, a systematic screening programme and randomised controlled trial of multi-factorial cardiovascular risk intervention in people with type 2 diabetes mellitus detected by screening. Trials. 2010;11:16.
    1. Janssen PG, Gorter KJ, Stolk RP, Rutten GE. Randomised controlled trial of intensive multifactorial treatment for cardiovascular risk in patients with screen-detected type 2 diabetes: 1-year data from the ADDITION Netherlands study. Br J Gen Pract. 2009;59:43–48.
    1. Sandbaek A, Griffin SJ, Rutten G. Stepwise screening for diabetes identifies people with high but modifiable coronary heart disease risk. The ADDITION study. Diabetologia. 2008;51:1127–1134.
    1. Sargeant LA, Simmons RK, Barling RS. Who attends a UK diabetes screening programme? Findings from the ADDITION-Cambridge study. Diabet Med. 2010;27:995–1003.
    1. WHO . Definition, diagnosis, and classification of diabetes mellitus and its complications: report of a WHO consultation. World Health Organization; Geneva, Switzerland: 1999.
    1. Griffin SJ, Little PS, Hales CN, Kinmonth AL, Wareham NJ. Diabetes risk score: towards earlier detection of Type 2 diabetes in general practice. Diabetes Metab Res Rev. 2000;16:164–171.
    1. Glumer C, Carstensen B, Sandbaek A, Lauritzen T, Jorgensen T, Borch-Johnsen K. A Danish diabetes risk score for targeted screening: the Inter99 study. Diabetes Care. 2004;27:727–733.
    1. Davies MJ, Heller S, Skinner TC. Effectiveness of the diabetes education and self management for ongoing and newly diagnosed (DESMOND) programme for people with newly diagnosed type 2 diabetes: cluster randomised controlled trial. BMJ. 2008;336:491–495.
    1. Ruige JB, de Neeling JN, Kostense PJ, Bouter LM, Heine RJ. Performance of an NIDDM screening questionnaire based on symptoms and risk factors. Diabetes Care. 1997;20:491–496.
    1. UK Prospective Diabetes Study Group Intensive blood-glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPDS 33) Lancet. 1998;352:837–853.
    1. Collins R, Armitage J, Parish S, Sleigh P, Peto R. MRC/BHF Heart Protection Study of cholesterol-lowering with simvastatin in 5963 people with diabetes: a randomised placebo-controlled trial. Lancet. 2003;361:2005–2016.
    1. Royal College of General Practitioners in Denmark . Type 2-diabetes in general practice—diagnosis and treatment. Royal College of General Practioners; Copenhagen, Denmark: 1999.
    1. Royal College of General Practitioners. McIntosh A, Hutchinson A, Home PD. Clinical guidelines and evidence review for type 2 diabetes: management of blood glucose. University of Sheffield; Sheffield, UK: 2001.
    1. Rutten GEHM, Verhoeven S, Heine RJ, De Grauw WJC, Cromme PVM, Reenders K. Dutch College of General Practitioners. Practice guideline diabetes mellitus type 2. Huisarts Wetensch. 1999;42:67–84.
    1. White IR, Thompson SG. Adjusting for partially missing baseline measurements in randomized trials. Stat Med. 2005;24:993–1007.
    1. Gooley TA, Leisenring W, Crowley J, Storer BE. Estimation of failure probabilities in the presence of competing risks: new representations of old estimators. Stat Med. 1999;18:695–706.
    1. Bradley C, editor. Handbook of psychology and diabetes: a guide to psychological measurement in diabetes research and practice. Psychology Press; London, UK: 1994.
    1. UK Prospective Diabetes Study Group Overview of 6 years' therapy of type II diabetes: a progressive disease. Diabetes. 1995;44:1249–1258.
    1. Spijkerman AM, Dekker JM, Nijpels G. Impact of diabetes duration and cardiovascular risk factors on mortality in type 2 diabetes: the Hoorn Study. Eur J Clin Invest. 2002;32:924–930.
    1. Olivarius NF, Beck-Nielsen H, Andreasen AH, Horder M, Pedersen PA. Randomised controlled trial of structured personal care of type 2 diabetes mellitus. BMJ. 2001;323:970–975.
    1. Carstensen B, Kristensen J, Ottosen P, Borch-Johnsen K. The Danish National Diabetes Register: trends in incidence, prevalence and mortality. Diabetologia. 2008;51:2187–2196.
    1. Doran T, Fullwood C, Gravelle H. Pay-for-performance programs in family practices in the United Kingdom. N Engl J Med. 2006;355:375–384.
    1. Royal College of General Practitioners in Denmark . Type 2 diabetes in general practice—an evidence based guideline. Royal College of General Practioners; Copenhagen, Denmark: 2004.
    1. Rutten GEHM, de Grauw WJC, Nijpels G. Dutch Guidelines on Type 2 Diabetes Mellitus. Dutch College of General Practitioners. Huisarts Wetensch. 2006;49:137–152.
    1. van den Donk M, Gorter KJ, Rutten GE. No negative effects of a multi-factorial, intensified treatment on self-reported health status, treatment satisfaction, and diabetes-related distress in screen-detected type 2 diabetes patients. The ADDITION-Netherlands study. Qual Life Res. 2010;19:509–513.

Source: PubMed

Sponsors and Collaborators

Medical Conditions

Drug Interventions

3
Subscribe